A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to fin

Trial Details

NCT ID
NCT05208762
Phase
PHASE1
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • PF-08046054
  • pembrolizumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Irvine, California, United States|33.66946,-117.82311
  • Sacramento, California, United States|38.58157,-121.4944
  • Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

  • Parts A and B:
  • Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types
  • Non-small cell lung cancer (NSCLC)
  • Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →